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Benzodiazepines are sedative/hypnotic drugs routinely prescribed to treat conditions such as anxiety, insomnia, and 
epilepsy.  Patients using these drugs are often monitored to ensure that the drugs are being used properly, as they are 
common targets of abuse due to their sedative effects.  The major metabolic pathway of benzodiazepines includes 
conjugation with glucuronides. Most laboratories choose to look for the free form of the drug rather than the 
conjugated metabolite; therefore, analysis of benzodiazepines requires enzyme hydrolysis of glucuronides for 
accurate detection of the drugs and drug metabolites in urine.  A recombinant β-glucuronidase enzyme, 
IMCSzyme
™
, was used in this experiment to reduce hydrolysis time.  Thomson eXtreme|FV 
® 
0.2µm PVDF 
(polyvinylidene fluoride filter vials) were used in place of solid phase extraction to further decrease the preparation 
time associated with analysis of benzodiazepines.  Analysis of liquid chromatography and tandem mass 
spectrometry (LC/MS/MS) data indicated that 30 minutes of hydrolysis at 55°C was ideal to break the glucuronide 
linkages associated with benzodiazepine metabolites. In addition, the sample preparation method was changed from 
a more time consuming Solid Phase Extraction Method (SPE) to a simple filtration method. A three day validation 
study confirmed that the method may be applied to the analysis of patient samples.   
 
Introduction: 
Benzodiazepines are prescribed for their uses as anti-
anxiety medications, anticonvulsants, or hypnotic 
drugs.  The sedative effects of these drugs make them 
targets of abuse; therefore, there is a need for 
evaluation of such drugs.  Benzodiazepines 
commonly monitored for such abuse include: 
nordiazepam, alprazolam (Xanax©), oxazepam 
(Serax©), clonazepam (Rivotril©), diazepam 
(Valium©), midazolam (Versed©), lorazepam 
(Ativan©), and temazepam (Restoril©).  Zolpidem 
(Ambien©) is incorporated into benzodiazepine 
analysis at Health Network Laboratories due to its 
similar sedative effects; however, zolpidem is not a 
benzodiazepine.  
 Many analysis methods contain either the 
benzodiazepine parent drugs listed above or the 
metabolites of the parent drugs.  The method used to 
monitor benzodiazepines in this laboratory consists 
of the following drugs: diazepam, nordiazepam 
(metabolite), α-hydroxyalprazolam (metabolite), 
oxazepam (parent drug or metabolite), 7-
aminoclonazepam (metabolite), hydroxymidazolam 
(metabolite), lorazepam, temazepam (parent drug or 
metabolite), and zolpidem.  Figure 1 depicts the 
relationship between parent drugs and metabolites 
that are used in benzodiazepine analysis at Health 
Network Laboratories. (Baselt, 2011) 
Most benzodiazepine metabolites excreted in urine 
contain glucuronide linkages. These conjugated 
linkages must be hydrolyzed for acceptable detection 
of the benzodiazepines with LC/MS/MS. (Webster, 
2007)  Enzyme hydrolysis has previously been a time 
consuming process. Formerly, abalone β-
glucuronidase was used to hydrolyze the glucuronide 
linkages.  This process required a three hour 
incubation. The use of the recombinant β-
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glucuronidase enzyme, IMCSzyme 
™
, significantly 
decreases the amount of time needed for enzyme 
hydrolysis. (Morris, Chester, Strickland, McIntire, 
2014)   
Analysis of benzodiazepines does require some type 
of sample preparation method after the enzyme 
hydrolysis to remove any particulate in the sample.  
Previously, solid phase extraction was used as the 
method of choice.  Unfortunately, solid phase 
extraction requires a great deal of time and the 
consumption of many solvents and buffers.  The use 
of the recombinant enzyme results in a cleaner 
sample, which allows for the use of a less stringent 




(polyvinylidene fluoride filter vials) significantly 
decreases the filtration time, as well as alleviating the 
need for additional solvents and buffers. (Thomson 
Instrument Company, 2015)  
The application of the recombinant β-glucuronidase 
enzyme, IMCSzyme 
™
, and the Thomson 
eXtreme|FV 
® 
was investigated to determine the 
effectiveness of the method in the analysis of 
benzodiazepines.   
Materials and Methods: 
Chemicals and Reagents 
 The IMCSzyme 
™ 
enzyme kit, containing the 
recombinant enzyme and rapid hydrolysis buffer, was 
purchased from IMCS (Integrated Micro-
Chromatography Systems).  Thomson eXtreme|FV
® 
0.2µm PVDF with pre-slit red caps and a 48 position 
vial filter press
 
were purchased from Thomson 
Instrument Company.  HPLC grade methanol was 
purchased from Fisher Scientific. The 1 mg/mL or 
100 µg/mL (Zolpidem) drug solutions used to make 
the working standards were purchased from Cerilliant 
Corporation.  HPLC grade water was purchased from 
Acros Corporation.   Formic Acid (96%) was 
purchased from the Sigma-Aldrich Company.  Drug 
free urine was obtained from patient samples 
identified as negative in a screening method.   Urine 
samples positive for benzodiazepines used for 
method validation were obtained from patient urine 
specimens previously identified as positive in a 
screening method. Control urine samples consisted of 
drug free urine spiked with the drug solutions 
obtained from Cerilliant Corporation.     
Analytical Procedure 
An LC check sample was created using 40% 
methanol, Standard #1, and the internal standard. The 
LC check was transferred to an auto sampler vial and 
set aside.  
 Internal standard (Table 3) was added to safe lock 
tubes containing 50 µL of rapid hydrolysis buffer for 
all samples.  The calibration curve was made up of 
five samples labeled Levels 1 through 5.  Levels 1 
and 2 were spiked with Standard #1 (Table 1), and 
Levels 3 through 5 were spiked with Standard #2 
(Table 2).  The curves contained 75, 300, 1,000, 
5,000 and 10,000 ng/mL (Level 1 to Level 5) of each 
drug, with the exception of Zolpidem.  The Zolpidem 
curve contained the concentrations 75, 300, 500, 
2,500, and 5,000 ng/mL (Level 1 to Level 5).   All 
sample tubes were capped and vortexed for 30 
seconds at 1750 rpm.  After the addition of 40 µL of 
IMSC β-glucuronidase, the tubes were capped and 
vortexed for 2 minutes at 1750 rpm.  All samples 
were incubated uncapped at 55°C±2°C for 30 
minutes.  The tubes were allowed to come to room 
temperature.  The hydrolyzed urine was added to 
40% methanol in Thomson eXtreme vials.  The 
Thomson filter plungers were pressed approximately 
¼ of the way down, and the tubes were vortexed at 2 
minutes at 1750 rpm.  The filter plungers were 
pressed the rest of the way down using the Thomson 
48 position press.   
Instrument Parameters 
The separation was performed using a Shimadzu LC 
system with a Restek Ultra Biphenyl column (5µm 
50 x 2.1 mm).  The mobile phases were 0.1% formic 
acid in HPLC water (A), and 0.1% formic acid in 
methanol (B), and the flow rate was 0.5000 mL/min.  
The initial mobile phase condition was 40% B at 0.01 
minutes, then 60% B at 1.50 minutes, which was 
ramped up to 85% B at 6.00 minutes, and further 
increased to 98% B at 6.80 minutes, and then brought 
back down to 40% at 6.50 minutes.  The program ran 
for a duration of 8.00 minutes.      
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Analysis requiring mass spectrometry was done on 
the ABSciex 3200® with Analyst and Multi Quant 
3.0 software. Ionization was carried out by Electron 
Spray Ionization (ESI), in conjunction with Multiple 
Reaction Monitoring (MRM).  Two MRM transitions 
were monitored for each analyte and internal 
standard.   
Validation 
After a suitable hydrolysis time was established, a 
three day validation study was used to confirm that 
the method was suitable for application to patient 
samples.  The validation utilized a calibration curve, 
limit of detection (LOD) and limit of quantitation 
(LOQ) samples in triplicate, low and high 
benzodiazepine concentration controls, and patient 
samples. Within run and between run accuracy and 
precision were evaluated. An ion suppression study 
was performed by adding drugs to urine samples pre 
extraction and post extraction for comparison.  
Results and Discussion 
Samples were initially analyzed using LC/MS/MS 
following a 15 minute hydrolysis at 55°C.  Due to 
discrepancies between the glucuronidated quality 
control results obtained and those expected, it was 
concluded that a longer incubation time was needed 
to fully hydrolyze the glucuronide linkages.  Samples 
were then incubated at 55°C for 30 minutes, which 
appeared to have hydrolyzed all glucuronide 
linkages.   
Calibration curves were made for each drug using the 
Level 1 through 5 samples.   The calibration curves 
yielded correlation coefficients in the range of 
0.99735< r <0.99864 for each drug.  The values for 
each analyte can be found in Table 4.   
Controls spiked with benzodiazepines used in the 
panel were within ±20% of their target range; 
meaning that the concentrations used in the 
calibration curves, and the calculated patient 
concentrations, were accurate. The percent 
coefficient of variation for the analytes ranged from 
1.8 % - 9.5 % between the three days of validation.  
This indicates that the amount of dispersion seen in 
the control concentrations throughout validation was 
small.   
Patient samples were analyzed, and the calculated 
concentrations were compared to those from the 
previous method using abalone β-glucuronidase and 
solid phase extraction.  Table 4 contains the mean 
percent difference in the patient samples for each 
analyte.  The patient concentrations using the new 
method were within ±20% of the patient 
concentrations using the older methodology, except 
for that of lorazepam, but most were greater than the 
older method indicating possibly more complete 
removal of the conjugated glucuronides by the new 
method.       
Ion suppression studies indicated that there was no 
existence of a significant difference in the analyte 
recovery when the analytes underwent the extraction, 
compared to samples where the analytes were added 
post extraction.  Table 5 shows that the percent 
recoveries for each analyte range from 93% to 115%; 
so the recoveries from each analyte addition method 
were similar.  The percent ion suppression in Table 5 
ranges from -11%-11%, which shows that the new 
methodology does not significantly suppress any 
analyte ions.  Therefore, there are no interfering 
substances in the urine matrix remaining from the 
less stringent filtration method.  
Conclusion 
This method shows the potential for the use of the 
recombinant β-glucuronidase enzyme, IMCSzyme 
™
, 
in conjunction with Thomson eXtreme|FV 
® 
0.2µm 
PVDF, in the analysis of benzodiazepines in urine.  
The use of the recombinant enzyme leads to a more 
rapid hydrolysis time, and a cleaner sample, in 
comparison to other enzymes used for glucuronide 
hydrolysis.(3)  The filter vials alleviate the need for 
solid phase extraction to clean up the samples before 
instrumental analysis.  This method will dramatically 
decrease the amount of time needed to run 
benzodiazepine analysis in clinical and forensic 
toxicology settings.   
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   Table 1- The benzodiazepines contained in the Standard #1 working solution. 
Analyte Final Concentration in 











Table 2- The benzodiazepines contained in the Standard #2 working solution. 
Analyte Final Concentration in 











  Table 3- The deuterated benzodiazepines contained in the Internal Standard working solution. 
Analyte Final Concentration in 
Standard Solution (ng/µL) 
Nordiazepam d5 4 
Oxazepam d5 4 
Diazepam d5 4 
Lorazepam d4 4 
Temazepam d5 4 
α- Hydroxyalprazolam d5 4 
7-Aminoclonazepam d4 4 






Table 4- The limit of detection (LOD), limit of quantitation (LOQ), linearity, correlation coefficients, expected 
control concentrations, percent coefficients of variation (%CV), patient comparison percent differences, and patient 

















 # of 
Patients 
Tested 
Diazepam 37.5 75 10,000 0.99829 110 4.2 N/A 0 
500 1.8 
α-Hydroxyalprazolam 37.5 75 10,000 0.99838 110 7.0 -5.05 4 
500 3.5 
Lorazepam 37.5 75 10,000 0.99864 110 5.7 24.2 1 
500 4.9 
Nordiazepam 37.5 75 10,000 0.99818 110 9.5 2.23 3 
500 2.4 
Oxazepam 37.5 75 10,000 0.99735 110 3.2 7.63 4 
500 4.7 
Temazepam 37.5 75 10,000 0.99782 110 6.8 2.42 3 
500 7.0 
Hydroxymidazolam 37.5 75 10,000 0.99808 N/A N/A -0.80 1 
N/A N/A 
7-Aminoclonazepam 37.5 75 10,000 0.99810 N/A N/A 8.87 3 
N/A N/A 




Table 5- The percent recovery and percent ion suppression for each analyte. 
 
 
Analyte % Recovery 
% Ion 
Suppression 
Diazepam 94 6 
α-Hydroxyalprazolam 89 11 
Lorazepam 91 9 
Nordiazepam 94 5 
Oxazepam 92 8 
Temazepam 91 8 
Hydroxymidazolam 111 -11 
7-Aminoclonazepam 99 0.6 
Zolpidem 107 -6 
